CliffBio
small molecule

MEPROBAMATE

MEPROBAMATE

Loss of exclusivity—loss of exclusivity
CompanyTaro Pharmaceutical Industries →See this company's full patent-cliff portfolio

Drug detail

Brand nameMEPROBAMATE
Active ingredientMEPROBAMATE
Strength400MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalMay 2011
Marketing statusDISCN

More from Taro Pharmaceutical Industries

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.